Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $16.23, down 5.31% on the session, giving a market capitalisation of $3.03B. On trailing twelve-month figures it carries a trailing P/E of -4.87, a net margin of 0.0%. Its beta of 1.08 implies it has historically moved more than the broad market.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Dyne Therapeutics, Inc. is most often compared with the following Healthcare names: